Ryoncil Sales for the Quarter Increase 60% to US$35.1M
Filed with ASX · · 2 pages · English
Watch Mesoblast's latest callMesoblast (ASX:MSB) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mesoblast (ASX:MSB) Q4 2026 Earnings CallRyoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication. Ryoncil® is the only FDA-approved product approved for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD),2 and will now be evaluated in a pivotal trial as part of a second-line regimen for adults with SR-aGvHD, a market appr
Earlier from Mesoblast
- Ryoncil® Sales Increase 60% in December Quarter to US$35.1M
- Mesoblast Announces Changes to Board of Directors' Leadership Roles
- Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit
- Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
- Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD
Later from Mesoblast
- FDA Acknowledges Effects on Pain Intensity Favor Rexlemestrocel-L, Confirms 12-Month Reduction in Back Pain Supports Product Efficacy
- Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment
- Ryoncil® Net Revenues Increase for the Quarter to US$30M
- Quarterly Activities/Appendix 4C Cash Flow Report
- High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast